The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

This chapter summarizes the landmark Veterans Affairs Cooperative Benign Prostatic Hyperplasia Study in patients with lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH) that randomized men to receive terazosin, the 5-alpha reductase inhibitor (5-ARI) finasteride, their combination, or placebo. This study demonstrated the benefit of alpha-blocker therapy for men with BPH symptoms but did not demonstrate an added benefit of combination alpha-blocker and 5-ARI therapy.